The therapeutic potential of stem cells is enormous. However, transplanted cells need to be matched to the donor to avoid rejection. Immune rejection of transplanted cells is mediated by the polymorphic human leukocyte antigen (HLA) proteins. HLA mismatches between donor and recipient prevent successful transplantation.
Universal Cells uses a proprietary genetic engineering technique to completely control HLA expression and create non-immunogenic cells for therapeutic applications.
Our patented technology is based on recombinant adeno-associated virus (AAV)-mediated gene targeting, which offers high accuracy and safety, and the best vehicle available for cellular delivery.